Latest Pertuzumab Stories
Clinical data from a Phase 1 investigator-sponsored study to be presented for MM-398 in high-grade glioma CAMBRIDGE, Mass., May 14, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
Median progression-free survival of 7.6 months reported for overall study population whose disease has progressed on a median of 4 prior therapies CAMBRIDGE, Mass., April 20, 2015 /PRNewswire/
RnRMarketResearch.com adds “Perjeta & Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023” to its store.
DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports
Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to research results released on Sunday.
MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A.
Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society
MarketResearchReports.Biz announces addition of new report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions
- To say in too many words; to express verbosely.
- To express in too many words: sometimes used reflexively.
- The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.